French drugmaker Sanofi said on Monday it would invest 400 million euros ($475.40 million) over five years in a new vaccine production site in Singapore.
The new site would provide Sanofi with the ability to produce innovative vaccines on a massive scale for Asia and respond to future pandemic risks, the company said in a statement.
The project is expected to create up to 200 local jobs, it added.
Sanofi said it expected to start the construction of the site in the third quarter of 2021 and be fully operational in the first quarter of 2026.
“The Singapore site will complement Sanofi’s existing manufacturing capacities in Europe and North America and will become a regional center of excellence for vaccines productionin Asia," the company said.
Drugmakers GSK, Sanofi begin new COVID-19 vaccine trial after setback last yearBritain’s GlaxoSmithKline and France’s Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate ... Coronavirus
Sanofi, GSK to supply 200 mln vaccine doses to WHO-backed COVAX allianceFrench drugmaker Sanofi and Britain’s GlaxoSmithKline will supply 200 million doses of their COVID-19 candidate vaccine to a global inoculation scheme ... Coronavirus
Sanofi confirms both COVID-19 shots could be available this yearSanofi’s two Covid-19 vaccines are entering new phases of trials in coming weeks and both could be available by the end of the year, said Thomas ... Coronavirus